Form 4: HealthEquity Founder Stephen Neeleman Executes Stock Transactions Under 10b5-1 Plan

Stephen Neeleman, Founder and Vice Chairman of HealthEquity, Inc., reports transactions involving the acquisition and disposal of common stock and stock options under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Stephen Neeleman, Founder and Vice Chairman of HealthEquity, Inc., filed a Form 4 detailing changes in beneficial ownership.
• On June 5, 2024, Neeleman executed transactions involving HealthEquity's common stock and stock options.
• These transactions were conducted under a Rule 10b5-1 trading plan adopted on December 8, 2023.
• Neeleman acquired 25,036 shares of common stock at $14 per share and disposed of 25,036 shares at a weighted average price of $85.0556.
• The sales occurred in multiple transactions with prices ranging from $85.00 to $85.22.
• Following these transactions, Neeleman directly owns 90,515 shares and indirectly owns 559,235 shares through the Stephen and Christine Neeleman Trust and 203,000 shares through Neeleman Family Holdings, LLC.
• Neeleman also exercised options to acquire 25,036 shares at $14.
• He continues to hold options to purchase additional shares at various exercise prices and expiration dates.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing reflects routine transactions under a pre-existing plan. There are no explicit positive or negative indicators about the company's performance.

Positives

• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, which can mitigate concerns about insider trading.
• The sale of shares at prices between $85.00 and $85.22 indicates a positive market valuation of HealthEquity's stock at the time of the transaction.

Negatives

• The sale of 25,036 shares by a founder and key executive could be perceived negatively by some investors, although it is part of a pre-planned strategy.

Risks

• Continued sales under the 10b5-1 plan could exert downward pressure on the stock price if the market interprets it as a lack of confidence by the founder.
• Changes in market conditions or the company's performance could impact the effectiveness of the trading plan.

Future Outlook

The document does not contain specific forward-looking statements, but the ongoing execution of the 10b5-1 trading plan suggests continued transactions in the future.

Industry Context

Form 4 filings are standard practice and provide transparency into the trading activities of company insiders. The use of a 10b5-1 plan is a common strategy for executives to manage their stock holdings while avoiding accusations of insider trading.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a common practice among executives at publicly traded companies, including those in the healthcare and technology sectors.
• Comparable companies like Teladoc Health and Cerner (now Oracle Health) also see regular Form 4 filings from their executives.
• The reported transactions are within the typical range of insider trading activity observed in similar companies.

Stakeholder Impact

• Shareholders may be interested in the trading activity of key executives as an indicator of confidence in the company.
• The transactions could have a minor impact on the stock price, depending on market perception.

Next Steps

• Monitor future Form 4 filings to track ongoing transactions under the 10b5-1 trading plan.
• Assess the impact of these transactions on the stock price and investor sentiment.

Key Dates